Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops (LeGoo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00985634
Recruitment Status : Unknown
Verified September 2009 by Pluromed, Inc..
Recruitment status was:  Recruiting
First Posted : September 28, 2009
Last Update Posted : September 28, 2009
Sponsor:
Information provided by:
Pluromed, Inc.

Tracking Information
First Submitted Date  ICMJE September 24, 2009
First Posted Date  ICMJE September 28, 2009
Last Update Posted Date September 28, 2009
Study Start Date  ICMJE September 2008
Estimated Primary Completion Date March 2010   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 25, 2009)
The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique. [ Time Frame: in operating room ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: September 25, 2009)
  • Total duration of the anastomosis, blood loss during the surgery, Time required to occlude the vessel, the number of units of blood transfused during hospitalization. [ Time Frame: in operating room (day of surgery) ]
  • Safety will be measured by comparing a composite of four serious adverse events experienced by the treated and control groups: death, graft occlusion, myocardial damage, and low post procedure cardiac output. [ Time Frame: one month post op ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops
Official Title  ICMJE Randomized Clinical Evaluation of LeGoo™ Internal Vessel Occluder Vs Traditional Vessel Loops
Brief Summary The primary purpose of this study is to demonstrate the clinical safety and efficacy of LeGoo™ in comparison to a standard vessel occlusion method (i.e. vessel loops). Although LeGoo™ is suitable for use in any vascular surgery where temporary vessel occlusion is desired, this study specifically focuses on the use of LeGoo™ in off-pump coronary bypass (OPCAB), as a most sensitive model of adverse changes that may occur at any vascular site.
Detailed Description

The purpose of this study is to evaluate the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. LeGoo is a device that is intended to be used during surgical procedures to temporarily occlude blood vessels while forming an anastomosis. LeGoo™ will be evaluated in subjects undergoing off-pump coronary artery by-pass (OPCAB) surgery. This is a prospective, randomized trial with a 30-day follow-up period. Half of the eligible patients will be randomized to the experimental group (LeGoo™); and the other half to the control group (standard vessel loops).

LeGoo™ is polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a "plug" form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer can never re-solidify.

The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.

Satisfactory hemostasis is defined by the surgeon who will quantitate his/her observation about the quality of the surgical field using the following scoring system:

  1. - Excellent hemostasis (no bleeding)
  2. - Minimal bleeding (bleeding does not interfere with suturing)
  3. - Modest bleeding (required intermittent use of another device to control bleeding at the site of the anastomosis)
  4. - Copious bleeding (required continuous use of another device)

"Excellent hemostasis" and "minimal bleeding" are considered "satisfactory hemostasis." Satisfactory hemostasis will constitute a treatment success for the purpose of evaluating the primary efficacy of LeGoo. The primary endpoint is the proportion of anastomoses in which satisfactory hemostasis is achieved.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Off Pump Coronary Artery Bypass Surgery
Intervention  ICMJE
  • Device: LeGoo
    LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
  • Device: Control
    Vessel loops
Study Arms  ICMJE
  • Experimental: LeGoo
    Subjects in this arm, which is assigned at random, will receive the study device.
    Intervention: Device: LeGoo
  • Active Comparator: Control
    Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
    Intervention: Device: Control
Publications * Wimmer-Greinecker G, Bouchot O, Verhoye JP, Perrault LP, Börgermann J, Diegeler A, Van Garsse L, Rastan AJ. Randomized clinical trial comparing a thermosensitive polymer (LeGoo) with conventional vessel loops for temporary coronary artery occlusion during off-pump coronary artery bypass surgery. Ann Thorac Surg. 2011 Dec;92(6):2177-83. doi: 10.1016/j.athoracsur.2011.07.003.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: September 25, 2009)
110
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2010
Estimated Primary Completion Date March 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects undergoing elective off pump coronary artery bypass (OPCAB) surgery where the surgeon prospectively plans to use a vascular occlusion device.
  2. >70% proximal stenosis of at least one target coronary artery, other than left main
  3. Age: between the ages 18 -79 years
  4. Gender: male and female
  5. Subject is willing and able to participate in a clinical research study and provides informed consent.
  6. Subject is able and willing to participate in required follow-up procedures.

Exclusion Criteria:

  1. Previous cardiac surgery.
  2. Left ventricular dysfunction (EF <40%)
  3. >50% of left main coronary artery stenosis
  4. Subjects with a logistic EuroScore equal to or greater than 10% as calculated by the euroscore.org calculator
  5. Emergent Surgery: Subjects undergoing surgery before the start of the next working day following catheterization
  6. Creatinine > 200 µmol/L
  7. Bilirubin > 21 µmol/L
  8. Subjects with chronic pulmonary disease [ FEV1 < 45% ]
  9. Any subject who is deemed by the investigator, for any reason, not suitable or able to participate in a clinical research study.
  10. Pregnant women. Women of childbearing age will require a pregnancy test within 10 days of the operation and will be excluded if the result is positive.
  11. Women who are lactating.
  12. Subjects who have undergone other investigational therapy within 30 days prior to the operation or who are scheduled to receive investigational therapy within six months of the operation.
  13. Subjects suspected to have one intra-myocardial artery among the coronary arteries to be bypassed during that surgery.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 79 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00985634
Other Study ID Numbers  ICMJE LeGoo EURO rev D
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party James Wilkie / Vice President Operations, Pluromed, Inc.
Study Sponsor  ICMJE Pluromed, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Pluromed, Inc.
Verification Date September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP